

Center for Molecular Imaging Innovation & Translation (CMIIT Goals

Goal 1: (80% Completed)

Optical Imaging Task Force

CMIIT plans to create a new Optical Imaging task force and organize an incubator meeting with the Optical Society of America

SNMMI Strategic Plan Goals that relates to this goal:

- Goal A: Advance the development and approval of nuclear medicine and molecular imaging technologies.
- Goal B: Facilitate and support the availability and clinical utilization of nuclear medicine and molecular imaging technologies.
- Goal E: Support and enhance the professional workforce and environment.

Current Progress: Eva Sevick, PhD, is chair of the CMIIT Optical Imaging Task Force. This task force will help identify, promote and facilitate collaboration and education in the translation of optical technologies used in molecular imaging and nuclear medicine. Dr. Sevick has organized part of a Continuing Education Session for the Mid-Winter meeting entitled "New First-in-Human Optical Tracers". She will be speaking in this session along with Drs. Zinn and Hasan. A similar Continuing Education session is scheduled for the Annual Meeting. (Updated: 01/14/2016)

Next Steps: We will follow up with Dr. Sevick at the Annual Meeting and provide support in the organization of optical imaging meetings as needed. Potential CMIIT co-sponsored optical-related meetings will be identified for 2016. (Updated: 01/14/2016)

Goal 2: (100% Completed)

Education

CMIIT will continue to co-sponsor meetings with the American Association of Cancer Research (AACR), as well as other Societies, to educate non-imaging scientists about the future of molecular imaging. CMIIT plans to continue offering educational sessions at the SNMMI Mid-Winter and Annual Meetings.

SNMMI Strategic Plan Goals that relates to this goal:

- Goal E: Support and enhance the professional workforce and environment.

Current Progress: Many educational session have been organized for the Mid-Winter and Annual Meetings. A "First-in-Human" Continuing Education session will take place Thursday, January 28, 2016 at the Mid-Winter Meeting. This will consist of sessions discussing "New First-in-Human Nuclear Tracers", "New First-in-Human Optical Tracers", "First-in-Human MR Molecular Imaging", and "FDA/CMS approvals and challenges". We will also co-sponsor a session on Friday, January 29, 2016 with CTN and RPSC on "Gallium-68 Imaging". At the Annual Meeting, a Categorical Session entitled "Molecular Imaging of Cancer Metabolism for the Radiation Therapy Treatment Planning in Brain and Prostate Cancers" is planned. CMIIT-sponsored Continuing Education Sessions at the Annual Meeting include, "Theranostic Nanoparticles", "New First-in-Human Optical Tracers", PET/MR I: Technical Advances", "PET/MR II: Clinical Applications", and "Molecular Imaging of Infection and Inflammation". Emerging Technologies sessions include, "The Masters Degree in Molecular Imaging for Technologists", "Standardization of Advanced PET/SPECT Data Acquisition and Analysis", and a to be determined session with the World Molecular Imaging Society (WMIS). A textbook Essentials of Molecular Imaging, co-authored by Henry VanBrocklin, Carolyn Anderson, Jonathan McConathy, Jeff Norenberg, and Todd Peterson, is in progress. The original goal was to submit by the end of 2015, but additional time will be needed for completion. (Updated: 01/14/2016)

Next Steps: The CMIIT BOD will discuss the progress of these various educational activities on upcoming conference calls. (Updated: 01/14/2016)

Goal 3: (10% Completed)

Nano-Technology

CMIIT will look into sponsoring a meeting on nano-technology in molecular imaging of cancer.

SNMMI Strategic Plan Goals that relates to this goal:

- Goal E: Support and enhance the professional workforce and environment.

Current Progress: Dr. Cathy Cutler has agreed to lead this initiative. (Updated: 05/20/2015)

Next Steps: The CMIIT BOD will discuss the progress of this initiative with Dr. Cutler (a BOD member) and identify steps that need to be taken into sponsoring a meeting on nano-technology in molecular imaging of cancer. (Updated: 01/14/2016)

Goal 4: (60% Completed)

Translation and Advancement of Molecular Imaging Agents

CMIIT will work together with the Clinical Trials Network on researching preclinical and basic science molecular imaging agents and why they are not being translated to the clinic and the cost of doing a clinical trial

SNMMI Strategic Plan Goals that relates to this goal:

- Goal A: Advance the development and approval of nuclear medicine and molecular imaging technologies.
- Goal B: Facilitate and support the availability and clinical utilization of nuclear medicine and molecular imaging technologies.
- Goal D: Advance and promote quality, value and safety of Molecular Imaging and Nuclear Medicine.
- Goal E: Support and enhance the professional workforce and environment.

Current Progress: A conference call was held between CMIIT members and members of WMIS to organize a Translational Workshop. This workshop has currently been postponed. In addition, the Translational Researcher Curriculum white paper was reviewed by the CMIIT Board of Directors. Feedback is being consolidated on the MI Translational Scientists Manuscript into one document. (Updated: 01/14/2016)

Next Steps: The CMIIT BOD will discuss these topics at an upcoming conference call. Final approval of the revised Translational Research Curriculum white paper by the CMIIT BOD will be sought, and the white paper will then be submitted for SNMMI approval. After approval by the SNMMI, a manuscript for publication will be submitted. (Updated: 01/14/2016)

Goal 5: (50% Completed)

Preclinical Imaging

CMIIT will consider certification and training workshops that focus on quality assurance and control that coincides with the preclinical guidance document.

SNMMI Strategic Plan Goals that relates to this goal:

- Goal A: Advance the development and approval of nuclear medicine and molecular imaging technologies.
- Goal D: Advance and promote quality, value and safety of Molecular Imaging and Nuclear Medicine.
- Goal E: Support and enhance the professional workforce and environment.

Current Progress: The Preclinical Task Force has reviewed the modules as identified for the "Preclinical Imaging in Small Laboratory Animals" – PRIMA workshop hosted by Bernd Pichler, PhD. The Preclinical Task Force members have given consideration into agreeing to a Memorandum of Understanding with several other professional societies, including EANM and WMIS, regarding coordination to establish a common curriculum and the offering of courses based on this curriculum. This MOU is currently under revision to come to terms with which all of the Societies can agree. It was suggested that both the Journal of Nuclear Medicine and the Molecular Imaging journal inform their submitters that preclinical research submitted to the journals should follow the criteria identified within the preclinical guidance document. The JNM editors have discussed this recommendation and will add the following language to the author guidelines: "For preclinical studies, the authors are encouraged to follow the "Guidance for Methods Descriptions Used in Preclinical Imaging Papers" published in Molecular Imaging Vol 12, No 7 (October 2013)." (Updated: 01/14/2016)

Next Steps: The CMIIT BOD will discuss this during the next conference call. (Updated: 01/14/2016)

Goal 6: (80% Completed)

Industry Partners Circle

CMIIT plans to look at ways to have the Industry Partners Meeting in the future.

SNMMI Strategic Plan Goals that relates to this goal:

- Goal A: Advance the development and approval of nuclear medicine and molecular imaging technologies.
- Goal B: Facilitate and support the availability and clinical utilization of nuclear medicine and molecular imaging technologies.
- Goal C: Increase appropriate utilization of Radionuclide Therapy.
- Goal D: Advance and promote quality, value and safety of Molecular Imaging and Nuclear Medicine.
- Goal E: Support and enhance the professional workforce and environment.

Current Progress: CMIIT will be having an Industry Partners Circle (IPC) just prior to the Mid-Winter Meeting on Wednesday, January 27, 2016. We have confirmed ten industry participants representing an array of large and small companies. Including our BOD and staff, we anticipate approximately twenty-five people to participate in the IPC. It will be suggested that BOD members draft a paper summarizing the IPC to potentially be published in JNM. (Updated: 01/14/2016)

Next Steps: Participate in the IPC and summarize accordingly. (Updated: 01/14/2016)

Goal 7: (20% Completed)

Increase CMIIT Membership

CMIIT will continue to work on increasing membership in the Center through outreach efforts, continuing education and task force initiatives

SNMMI Strategic Plan Goals that relates to this goal:

- Goal E: Support and enhance the professional workforce and environment.

Current Progress: A new Chair of the CMIIT Membership Task Force will be appointed. Previously, the Task Force discussed a proposed new CMIIT award that is intended to highlight those investigators who have been successful in translating their innovation into the clinic. Cathy Cutler, PhD, suggested the award should be for someone who is very innovative (more of an award for a particular accomplishment) for something that stands out in the field. This award would be presented at the annual meeting. The CMIIT Membership Task Force also discussed improvements to the CMIIT website and Dr. McConathy mentioned the recent conference call with Mike Haka, PhD, Chair of the CMIIT Website Task Force and his thoughts on providing more of an interactive website for both CMIIT and RPSC members. The CMIIT Membership Task Force also discussed the importance of outreach efforts to other Councils and Centers. There was a suggestion to have CMIIT Board members sit on the other Council and Center Board of Directors (BOD) as non-voting, ex-officio members. Dr. Herscovitch made the comment that it is better to have members of the other Council's and Center's BOD sit on the CMIIT Board as non-voting, ex-officio members. Todd Peterson reminded everyone that both the RPSC President and CVC President are currently ex-officio members of the CMIIT BOD and that the CMIIT Operating Procedures state that the President of CMIIT can appoint up to four council representatives to sit on the CMIIT BOD. Suggestions were made to have representatives from the Brain Imaging Council, the Nuclear Oncology Council, the Clinical Trials Network, and the Young Professional Council as ex-officio, non-voting members of the CMIIT BOD. (Updated: 01/14/2016)

Next Steps: The current CMIIT BOD will decide which Councils to add to the CMIIT BOD as non-voting members at the Annual Meeting. The proposal for a CMIIT award will be reviewed by the CMIIT BOD with a goal of submitting to the SNMMI at the 2016 or 2017 Annual Meeting. 2015-2016 CMIIT Leadership Officers Jonathan McConathy, MD, PhD President Buck Rogers, PhD Vice President Neil Vasdev, PhD Secretary/Treasurer Todd Peterson, PhD Immediate Past-President Board Members Walter Akers, DVM, PhD Steve Y. Cho, MD Cathy S. Cutler, PhD W. Barry Edwards, PhD Edward Graves, PhD Dima Hammoud, MD Kayvan Keshari, PhD Jeffrey Norenberg, PharmD, PhD Neil Petry, MS, RPh, BCNP Thomas Reiner, PhD Sally Schwarz, MS, RPh, BCNP Hyunsuk Shim, PhD Aileen M. Staffaroni, MS, CNMT Lesley Flynt, MD (Intern) Suzanne Lapi, PhD (Ex Officio) Thomas Schindler, MD (Ex Officio) (Updated: 01/14/2016)